Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEK162 in Noonan syndrome hypertrophic cardiomyopathy
2011-003392-10Phase 2Unknown
- Sponsor
- Novartis
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of binimetinib in Noonan syndrome and hypertrophic cardiomyopathy (HCM), sponsored by Novartis. Primary endpoint: Left ventricular mass and left ventricular mass index. Status: unknown.
02
Drugs
binimetinib
03
Conditions
Noonan syndromehypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2011-003392-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003392-10.